Molecular targeted therapies offer great hope in lung cancer because they are supposed to act upon biologic abnormalities specific to cancer cells. In the present review, we will describe the major pathways of tumor cell growth, apoptosis, angiogenesis and invasion as well as the targeted therapies interacting with these pathways. We will provide an overview of the trials involving targeted therapies in lung cancer, along with the specific problems related to the development of these new therapies.
Copyright John Libbey Eurotext 2003.